Literature DB >> 29197994

Serum lipids and risk of obesity-related cancers in postmenopausal women.

Geoffrey C Kabat1, Mimi Y Kim2, Rowan T Chlebowski3, Mara Z Vitolins4, Sylvia Wassertheil-Smoller2, Thomas E Rohan2.   

Abstract

PURPOSE: Obesity, which is commonly accompanied by dyslipidemia, is associated with an increased risk of certain cancers. However, the association of serum lipids with specific obesity-related cancers is unclear.
METHODS: We examined the association of baseline lipids (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides) with risk of developing seven obesity-related cancers in a subcohort of 24,208 participants in the Women's Health Initiative. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for quartiles of lipids with cancers of the breast, colorectum, pancreas, endometrium, ovary, and kidney, and multiple myeloma.
RESULTS: Total cholesterol and LDL-C showed no association with these outcomes. HDL-C was inversely associated, and triglycerides were positively associated, with several cancers. However, after adjustment for other lipids or insulin, consideration of preclinical disease, and exclusion of women taking statins, most associations were attenuated and no longer significant. Only the inverse association of HDL-C with pancreatic cancer (HR for highest vs. lowest quartile 0.52, 95% CI 0.32-0.85, p for trend 0.007) and the positive association of triglycerides with kidney cancer (HR for highest vs. lowest quartile 3.21, 95% CI 1.63-6.33, p for trend = 0.0001) remained significant. However, the inverse association of HDL-C with pancreatic cancer was no longer significant when women who lost substantial weight before diagnosis were excluded.
CONCLUSIONS: Our results suggest that when possible sources of confounding and bias are taken into account there are few robust associations of lipids with obesity-related cancers.

Entities:  

Keywords:  Cancer; High-density lipoprotein cholesterol; Lipids; Postmenopausal women; Triglycerides

Mesh:

Substances:

Year:  2017        PMID: 29197994     DOI: 10.1007/s10552-017-0991-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  6 in total

1.  Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer.

Authors:  Sarah Irvin; Megan A Clarke; Britton Trabert; Nicolas Wentzensen
Journal:  Cancer Causes Control       Date:  2020-07-20       Impact factor: 2.506

2.  Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides.

Authors:  Britton Trabert; Cassandra A Hathaway; Megan S Rice; Eric B Rimm; Patrick M Sluss; Kathryn L Terry; Oana A Zeleznik; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-08-17       Impact factor: 4.090

Review 3.  Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis.

Authors:  Abdollah Mohammadian-Hafshejani; Catherine M T Sherwin; Saeid Heidari-Soureshjani
Journal:  J Prev Med Hyg       Date:  2020-10-06

4.  Low high-density lipoprotein cholesterol levels are associated with malignant intraductal papillary mucinous neoplasms: A multicenter study.

Authors:  Cheng Wang; Tingting Lin; Xinru Wang; Zhicheng Yu; Xiaoling Zhuge; Wenjing Cui; Miaomiao Wang; Zhongqiu Wang; Chuangen Guo; Xiao Chen
Journal:  Lipids Health Dis       Date:  2021-08-28       Impact factor: 3.876

5.  Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer.

Authors:  Pik-Fang Kho; Frederic Amant; Daniela Annibali; Katie Ashton; John Attia; Paul L Auer; Matthias W Beckmann; Amanda Black; Louise Brinton; Daniel D Buchanan; Stephen J Chanock; Chu Chen; Maxine M Chen; Timothy H T Cheng; Linda S Cook; Marta Crous-Bous; Kamila Czene; Immaculata De Vivo; Joe Dennis; Thilo Dörk; Sean C Dowdy; Alison M Dunning; Matthias Dürst; Douglas F Easton; Arif B Ekici; Peter A Fasching; Brooke L Fridley; Christine M Friedenreich; Montserrat García-Closas; Mia M Gaudet; Graham G Giles; Ellen L Goode; Maggie Gorman; Christopher A Haiman; Per Hall; Susan E Hankinson; Alexander Hein; Peter Hillemanns; Shirley Hodgson; Erling A Hoivik; Elizabeth G Holliday; David J Hunter; Angela Jones; Peter Kraft; Camilla Krakstad; Diether Lambrechts; Loic Le Marchand; Xiaolin Liang; Annika Lindblom; Jolanta Lissowska; Jirong Long; Lingeng Lu; Anthony M Magliocco; Lynn Martin; Mark McEvoy; Roger L Milne; Miriam Mints; Rami Nassir; Geoffrey Otton; Claire Palles; Loreall Pooler; Tony Proietto; Timothy R Rebbeck; Stefan P Renner; Harvey A Risch; Matthias Rübner; Ingo Runnebaum; Carlotta Sacerdote; Gloria E Sarto; Fredrick Schumacher; Rodney J Scott; V Wendy Setiawan; Mitul Shah; Xin Sheng; Xiao-Ou Shu; Melissa C Southey; Emma Tham; Ian Tomlinson; Jone Trovik; Constance Turman; Jonathan P Tyrer; David Van Den Berg; Zhaoming Wang; Nicolas Wentzensen; Lucy Xia; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Wei Zheng; Penelope M Webb; Deborah J Thompson; Amanda B Spurdle; Dylan M Glubb; Tracy A O'Mara
Journal:  Int J Cancer       Date:  2020-08-07       Impact factor: 7.396

6.  Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: An analysis of linked SEER-Medicare data.

Authors:  Kara A Michels; Timothy S McNeel; Britton Trabert
Journal:  Gynecol Oncol       Date:  2019-09-05       Impact factor: 5.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.